|Articles|March 25, 2016

Market Access Capabilities for a Value-Driven Marketplace Spon Opp

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan

Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeutics

Market Access Capabilities for a Value-Driven Marketplace Spon Opp

Related Content

Nuvation Bio’s Global Strategy

Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform

Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik

Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeutics

FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease

Trending on PharmExec

The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan

Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeutics

FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease

Educating Patients About GLP-1s: Q&A with Kristen Hartzell, PharmD

Nuvation Bio’s Approach to Building a Compelling Narrative